| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | |
|---|---|---|---|---|
| Cash | NaN | NaN | 6,904,185 | |
| Cash and cash equivalents | 1,127,619 | 986,996 | NaN | |
| Marketable securities | 11,847,305 | 14,801,267 | 3,091,772 | |
| Deposits and other receivables | NaN | 18,200 | NaN | |
| Other receivables | 16,800 | NaN | NaN | |
| Prepaid expenses | 714,121 | 774,095 | 1,150,291 | |
| Total current assets | 13,705,845 | 16,580,558 | 11,146,248 | |
| Technology license | 14,086,999 | 14,086,999 | 14,086,999 | |
| Goodwill | 10,498,539 | 10,498,539 | 10,498,539 | |
| Investment in oravax medical | NaN | NaN | 1,500,000 | |
| Total non-current assets | 24,585,538 | 24,585,538 | 26,085,538 | |
| Total assets | 38,291,383 | 41,166,096 | 37,231,786 | |
| Lease liability | NaN | NaN | 0 | |
| Trade and other payables | 1,383,001 | 2,445,346 | 3,180,662 | |
| Due to mymd fl shareholders | 29,982 | 29,982 | 29,982 | |
| Dividends payable | 594,397 | 365,970 | 89,728 | |
| License fees payable | 35,018 | 533,744 | 337,130 | |
| Derivative liability | 1,647,000 | 2,157,000 | 2,896,000 | |
| Total current liabilities | 3,689,398 | 5,532,042 | 6,533,502 | |
| Contingent consideration payable | 10,909,000 | 10,909,000 | 9,380,000 | |
| Total non-current liabilities | 10,909,000 | 10,909,000 | 9,380,000 | |
| Total liabilities | 14,598,398 | 16,441,042 | 15,913,502 | |
| Convertible preferred stock, value-Series FConvertible Preferred Stock | NaN | NaN | 0 | |
| Convertible preferred stock discount-Series FConvertible Preferred Stock | NaN | NaN | 0 | |
| Convertible preferred stock derivative-Series FConvertible Preferred Stock | NaN | NaN | 0 | |
| Convertible preferred stock, value-Series FOne Convertible Preferred Stock | NaN | NaN | 0 | |
| Convertible preferred stock discount-Series FOne Convertible Preferred Stock | NaN | NaN | 0 | |
| Convertible preferred stock, value-Series GConvertible Preferred Stock | NaN | NaN | 8,804,000 | |
| Convertible preferred stock discount-Series GConvertible Preferred Stock | NaN | NaN | 6,938,000 | |
| Convertible preferred stock, value-Series HConvertible Preferred Stock | NaN | NaN | 7,000,000 | |
| Convertible preferred stock, value-Series GConvertible Preferred Stock | 8,802,000 | 8,802,000 | NaN | |
| Convertible preferred stock discount-Series HConvertible Preferred Stock | NaN | NaN | 2,729,083 | |
| Convertible preferred stock discount-Series GConvertible Preferred Stock | 6,938,000 | 6,938,000 | NaN | |
| Series h convertible preferred stock derivative-Series HConvertible Preferred Stock | NaN | NaN | 1,837,000 | |
| Convertible preferred stock, value-Series HConvertible Preferred Stock | 3,115,000 | 3,115,000 | NaN | |
| Convertible preferred stock, value-Series IConvertible Preferred Stock | NaN | NaN | 2,697,977 | |
| Convertible preferred stock discount-Series HConvertible Preferred Stock | 168,621 | 168,621 | NaN | |
| Total mezzanine equity | NaN | NaN | 6,997,894 | |
| Convertible preferred stock derivative-Series HConvertible Preferred Stock | 1,837,000 | 1,837,000 | NaN | |
| Preferred stock, value-Series IConvertible Preferred Stock | NaN | NaN | 0 | |
| Total mezzanine equity | 2,973,379 | 2,973,379 | NaN | |
| Preferred stock, value-Series DConvertible Preferred Stock | NaN | NaN | 144,524 | |
| Preferred stock, value | 144,524 | 144,524 | NaN | |
| Common stock, par value 0.001, 1,250,000,000 shares authorized, 7,853,429 and 7,690,403 shares issued and outstanding as of march 31, 2026 and december 31, 2025, respectively | 7,846 | 184,502 | 179,812 | |
| Additional paid in capital | 166,218,419 | 165,545,382 | 151,558,433 | |
| Accumulated deficit | -145,651,183 | -144,122,733 | -137,562,379 | |
| Total stockholders equity | 20,719,606 | 21,751,675 | 14,320,390 | |
| Total liabilities and stockholders equity | 38,291,383 | 41,166,096 | 37,231,786 | |
Q C TECHNOLOGIES, INC. (QCLS)
Q C TECHNOLOGIES, INC. (QCLS)